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Abstract: The burden of late onset sepsis (LOS) and necrotizing enterocolitis (NEC) remains high for 
newborns in low- and high-income countries. Very preterm born infants born below 32 weeks gestation are at 
highest risk because their immune system is not yet adapted to ex-utero life, providing intensive care frequently 
compromises their skin or mucosa and they require a long duration of hospital stay. An epidemiological overview 
is difficult to provide because there is no mutually accepted definition available for either LOS or NEC. LOS 
incidence proportions are generally reported based on identified blood culture pathogens. However, discordance 
in minimum day of onset and whether coagulase negative staphylococci or fungi should be included into the 
reported proportions lead to variation in reported incidences. Complicating the comparison are the absence of 
biomarkers, ancillary lab tests or prediction models with sufficiently high positive and/or negative predictive 
values. The only high negative predictive values result from negative blood culture results with negative lab results 
allowing to discontinue antibiotic treatment. Similar difficulties exist in reporting and diagnosing NEC. Although 
most publications base their proportions on a modified version of Bell’s stage 2 or 3, comparisons are made 
difficult by the multifactorial nature of the disease reflecting several pathways to intestinal necrosis, the absence of 
a reliable biomarker and the unclear differentiation from spontaneous intestinal perforations. Comparable reports 
in very low birthweight infants range between 5% and 30% for LOS and 1.6% to 7.1% for NEC. Evidence based 
guidelines to support treatment are missing. Treatment for LOS remains largely empirical and focused mainly 
on antibiotics. In the absence of a clear diagnosis, even unspecific early warning signals need to be met with 
antibiotic treatment. Cessation after negative blood culture is difficult unless the child was asymptomatic from 
the beginning. As a result, antibiotics are the most commonly prescribed medications, but unnecessary exposure 
may result in increased risk for mortality, NEC, further infections and childhood obesity or asthma. Finding 
ways to limit antibiotic use are thus important and have shown a large potential for improvement of care and 
limitation of cost. Over recent decades, none of the attempts to establish novel therapies have succeeded. LOS 
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of LOS and NEC and for a subsequently more successful development of novel therapies as these often address 
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Introduction
Although the rate of late onset sepsis (LOS) in newborns 
has modestly decreased in some areas as a result of ongoing 
quality improvement (QI) measures, LOS remains a 
frequent and devastating problem for newborns in high- 
and low-income countries (1). Current cause specific 
mortality rate per 1,000 live births below 29 weeks gestation 
for LOS is approximately 22 (2). LOS concern infections 
acquired during hospital stay, i.e., healthcare associated 
infections/nosocomial infections, which are most often 
defined as clear clinical evidence of infection and at least 
one microbiologically relevant positive result derived from 
a blood culture [including coagulase negative staphylococci 
(CoNS) and fungal pathogens] taken after 72 hours or 
3 days of life (3,4). 
Reports about changes of the burden of necrotizing 
enterocolitis (NEC) are more ambiguous in comparison. 
Whereas Horbar et al. report that 76% of neonatal 
intensive care units (NICUs) in the United States (US) 
reached the same low NEC incidence rate in 2014 as the 
best quantile of NICUs had reached in 2005 (3), a study 
from the National Institute of Child Health and Human 
Development (NICHD) of extremely preterm infants born 
between 2000–2011 reported that NEC related deaths rose 
from 23% to 30%, whereas overall mortality declined (2). 
The risk of acquiring either LOS or NEC is inversely 
proportional to gestational age (GA) (5,6). Preterm infants 
are at higher risk for LOS for several reasons. The immune 
system of preterm infants exhibits distinct functions geared 
towards the fetus being well-equipped for life in utero and 
for appropriate mediation of the transition to ex-utero life 
at term. But when born preterm, the child’s immune system 
is not yet adapted to ex-utero life (7). Preterm infants often 
do not have a vernix caseosa because its production begins 
during the third trimester, their skin is thinner and takes 
longer to develop a barrier function than in term born 
infants, and the majority of maternal immunoglobulin G 
(IgG) antibody transfer occurs during the last trimester 
so that preterm born infants are deplete of IgG. This all 
impairs a robust immune response to pathogens (8,9). 
Another reason preterm infants are at higher risk for 
infection is because natural barriers towards infection often 
need to be compromised in order to be able to provide 
intensive care: the skin is affected by tapes, catheters, 
surgery, etc.; and the mucosa by ventilation, nutrition, 
medication, etc. This may disable the infant’s defense 
against pathogens (10). Lastly, length of stay in a hospital 
environment is also inversely proportional to GA and thus 
submit preterm infants to hospital pathogens for long 
periods of time (11). 
Although an impaired immune system is also believed 
to play a role in NEC (12), its pathogenesis is less well 
understood. It appears to be multifactorial, reflecting several 
different pathways to intestinal necrosis with different 
inciting factors. Complicating the issue is that NEC may well 
be more than one disease with separate pathogenesis (12). 
NEC mostly occurs in infants born prematurely as its 
etiological factors are largely related to immaturity of the 
gastrointestinal tract. After birth, the neonatal gut must 
acquire a healthy complement of commensal bacteria. 
Disruption or delay of this critical process, leading to 
deficient or abnormal microbial colonization of the gut, 
has been implicated as key risk factor in the pathogenesis of 
NEC (6,13,14). What follows is profound inflammation and 
intestinal injury (15,16).
LOS and NEC have long-term implications for 
newborns: a 2013 systematic review and meta-analysis 
on neurodevelopmental outcome of very low birthweight 
infants (<1,500 g, VLBW) with neonatal sepsis found 
17 studies matching their criteria which indicate that 
the diagnosis of neonatal sepsis in VLBW infants is 
associated with an increased risk of one or more long-
term neurodevelopmental impairments including higher 
incidence of cerebral palsy (5). NEC and surgery for NEC 
have also been associated with increased risk of adverse 
neurodevelopmental outcome at two years of age (17-19). 
The financial impact of NEC is estimated at $1 billion per 
year in the US alone (15). In a study of extremely preterm 
born infants surviving to 36 weeks postmenstrual age, the 
presence of LOS or NEC independently increased the risk 
of late death or survival with neurosensory impairment (20).
Among pediatric acute care hospitals, the prevalence 
of infections was highest in pediatric intensive care units 
(15.5%, 95% CI: 11.6–20.3%) and NICUs (10.7%, 9.0–
12.7%). This review will focus on literature about LOS 
or NEC in very preterm infants (<32 weeks gestation) 
or VLBW infants in order to cover the highest risks of 
acquiring either illness (21). We will compare LOS and 
NEC incidence proportions between large geographically 
defined cohorts and reveal how QI measures rather than 
novel interventions currently drive the change towards 
better outcome.
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Epidemiology
Because differences exist in the definition of LOS and 
NEC between health care providers, it is difficult to 
establish an epidemiological overview for either: Most 
use 3 days or 72 hours after birth as onset to differentiate 
nosocomial infections from infections acquired via the 
mother (early onset sepsis, EOS). However, some use 
48 hours or 2 days and again others use 7 days as threshold 
(Table 1). Usually the definition includes positive blood 
culture and clinical signs of infection, but sometimes 
blood culture alone is deemed sufficient (3). Some require 
additional clinical signs or two independent blood samples 
to verify coagulase negative staphylococci (CoNS) (26,37). 
This makes sense as it better allows differentiating true 
CoNS infestation from a contamination of the blood 
sample because CoNS is a common colonizer of the 
human skin (38). However, most include CoNS as they do 
any other culture proven sepsis. Lastly, some publications 
specifically state the requirement of at least 5 days of 
antibiotic treatment in addition to the positive culture 
result to define an LOS episode (3,22-24,34,36). 
If we tolerate some constraint in scientific rigor, as is 
recommended for the purpose of uncovering potential for 
QI (39), then we may interpret some of the reported LOS 
incidence proportions as comparable, even when their 
definitions do not match. Publications using 2 or 3 days 
as onset are roughly comparable as the peak incidence of 
LOS is between the 10th and 22nd day of life (4) and EOS 
prevalence is considerably lower than that of LOS (40), 
particularly if only cases that present on the 3rd day of 
life are driving the difference. Additional requirements 
including the presence of clinical signs or at least 5 days 
antibiotic treatment should not disable comparison as in 
most cases blood cultures are cultivated upon clinical signs 
and positive cultures usually receive 5 or more days of 
antibiotic treatment (21). Comparisons should nevertheless 
be treated with caution, particularly if minimum day of 
onset is after day 7 of life, CoNS are excluded, or if CoNS 
require 2 blood samples. The latter two are because CoNS 
account for 53.2–77.9% of LOS in industrialized countries 
and 35.5–47.4% in some developing regions (4). This 
means that a different onset or handling of CoNS will 
have an impact on reported proportions. Another issue to 
observe is the population used as denominator and whether 
it encompasses a geographical region. For instance, Grisaru 
et al. report LOS proportions for two time periods in 
Israel: 33.4% for 2001–2005 and 28.6% for 2006–2010, 
respectively (28). This is higher than the 26% reported by 
Vergnano et al. from England for 2007–2008 (22). Even 
though both reported proportions for VLBW infants, the 
comparability is limited because Israel’s data is population 
based whereas the data for England represents 12 units 
dedicated to data collection. Also, Israel restricted its 
population to singleton births which may have a different 
risk for adverse outcome than multiple births (41). 
Comparability between studies is equally an issue 
in reported NEC proportions, largely because of the 
multifactorial nature of the disease. Whereas most report 
their NEC incidence based on the modified version of Bell’s 
stage 2 or higher (including specific radiologic signs, i.e., 
pneumatosis intestinalis) (42), some diagnose NEC at a 
different stage or avoid using Bell’s criteria altogether (6,43). 
Spontaneous intestinal perforation (SIP) is an illness with 
sometimes similar symptoms but different pathogenesis 
from NEC. However, most publications do not specify if 
cases of SIP were excluded from their NEC incidence prior 
to reporting (Table 1). Therefore, comparisons between 
health care providers need to be treated with caution. 
Table 2 lists LOS and NEC incidence proportions of 
several large, geographically defined, prospective neonatal 
data collections for the last two decades. This list does not 
claim to be exclusive but it does contain results from the best 
known large neonatal data collections from Australia/New 
Zealand, Canada, France, Germany, Israel, Japan, Korea, 
Spain, Sweden, Switzerland and the US (3,24,25,27-35,45). 
LOS proportions range from 5% in Japan to 29.4% in 
Spain for VLBW infants whereas NEC proportion range 
from 1.6% again in Japan to 7.1% in the US. Whenever 
available, we listed 2 consecutive periods that inform 
on a development over time. Most impressive is the one 
reported by the Vermont Oxford Network (VON) (Horbar 
et al.) on the development of LOS among VLBW from an 
internationally comparable 21.9% in 2005 to a low 10.1% 
9 years later. In the same study, the proportion of NEC 
was reduced from 7.1% to 5.2%. Horbar et al. maintain 
“these results illustrate the magnitude and pace of improvement 
that has occurred over the decade and describe the variation in 
outcomes that persists among different NICUs.” (3). Although 
we are far from being able to infer causality on the part 
of QI on outcome, we can assume that collaboration in a 
neonatal network such as the VON with its improvement 
programs, teaching and reporting do have an effect 
(46,47). This is illustrated with enhanced statistical rigor 
also by the Canadian Neonatal Network. Their Evidence 
Based Practice for Improving Quality (EPIQ) program 
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demonstrated improvement in LOS in a cluster randomized 
setting in 2005 (29) and in an observational setting using 
EPIQ in LOS and NEC in 2017 (33) (Table 2).  
Also reporting improvement over time based on 
improved peri- and neonatal care practices are Stoll et al. 
for the NICHD and Kim et al. for the Korean Neonatal 
Network (Table 2). Of the commonly reported neonatal 
outcomes, LOS is unique in so far that the substantial 
decreases observed in recent years is compared with little 
change in the previous decades. This decrease has occurred 
without any specific new therapy or intervention having 
been introduced (44).
As mentioned, CoNS are the most prominent pathogens 
of LOS. They are however not as virulent as Gram-
negative bacteria and possibly fungi which partly explains 
the lower rate of short-term infectious complications as 
well as mortality associated with CoNS sepsis (48,49). 
Makhoul et al. for instance reported 6.3-fold and 12.3-fold 
increased risk of early mortality associated with Klebsiella 
and Pseudomonas sepsis when compared with CoNS (50). 
However, the risk of neurodevelopment sequelae, such as 
cognitive and psychomotor impairment, cerebral palsy, and 
vision impairment was independent of the type of pathogen, 
indicating that CoNS are capable to exert a long-term 
detrimental effect on the host (4). In a recent systematic 
review, Dong et al. concluded that VLBW infants may differ 
from more mature neonates in terms of disease burden 
and clinical course of LOS caused by Gram-negative 
bacteria. Using strategies targeting Gram-negative bacteria, 
new epidemiologic studies aided by advanced molecular 
techniques may help to develop an anti-sepsis protocols 
specialized for VLBW infants (51).
Apart from CoNS as the most common finding from 
blood cultures in all publications, the other pathogens 
seem to vary regionally. In their study on neonatal 
infections in England, the NeonIN group convincingly 
reveal how the identified strains match other reports 
from the UK or Germany but are different from infection 
surveillance reports from the US or Australia (22). Similar 
geographically dependent differences are reported in Asia 
or Spain (52,53).
Diagnosis
Another factor exacerbating an epidemiological overview 
over LOS and NEC is that diagnosing them in clinical 
practice requires skill and experience. To date, no clear 
biomarker with high positive and negative predictive 
value (PPV/NPV) exists so that diagnosis is subjective and 
variable (54). 
Symptoms of LOS are often subtle and non-specific 
since virtually every clinical finding has been associated with 
sepsis (21). The low (mostly 1 mL or even lower) volume of 
bacterial blood samples typically taken for culture have low 
sensitivity (7). PPV is poor because there is no consensus on 
how to determine whether the most common isolates, i.e., 
CoNS, represent true pathogens or contaminants picked up 
during sampling (55). NPV is difficult to determine because 
there is no consensus on how to diagnose clinically relevant 
sepsis where a positive blood culture is missing. Of the 
16 reports listed in Tables 1,2, only 3 account separately of 
culture negative sepsis. 
To support diagnosis, ancillary lab tests are commonly 
used, such as C-reactive protein, interleukins, procalcitonin 
and others. If they are applied correctly, i.e., using postnatal 
and GA specific reference values, these tests have good 
NPV but poor PPV (56,57). This is important because at 
least in the absence of a positive blood culture, negative lab 
values allow discontinuation of antibiotic treatment. 
A promising development is the ability to identify 
pathogens in the blood by analyzing their DNA via 
polymerase chain reaction (PCR). Compared with the 
conventional culture technology, PCR technologies yield 
results faster, in a higher sensitivity and with a much smaller 
sample volume. Recently developed PCR-based diagnostic 
platforms are highlighted by a low contamination rate (4). 
This could allow better differentiating between true and 
contaminated CoNS infestation. However, Molecular assays 
do not yet have sufficient sensitivity to replace microbial 
cultures in the diagnosis of LOS (58). Until these tests 
become available, clinicians will need to continue to make 
preliminary decisions based on nonspecific signs and tests 
with poor PPV, particularly in the extremely preterm infants 
where 1 mL blood samples are difficult to obtain. 
In recent years it has however become clear that the 
absence of certainty cannot be met by just withholding 
treatment or providing full treatment as either will affect 
the child’s development and in the case of overtreatment 
lead to microbial resistance (see below). Instead, constant 
reassessment is required. For this reason, prediction 
models with clinical parameters have been developed to 
facilitate preliminary sepsis diagnosis and the initiation of 
antimicrobial therapy. A recent systematic review however 
concluded that these models should be considered as 
guidance rather than an absolute indicator because of their 
limited diagnostic accuracy (59).
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The initial stages of NEC are also comprised of non-
specific signs and symptoms which overlap with other 
conditions such as sepsis, apnea, or feeding intolerance. 
The diagnosis of NEC is based on a combination of 
clinical, radiological, and lab findings. A reliable biomarker 
is missing. Although disputed by many as inaccurate, 
incomplete or outdated (6,43), the most common clinical 
staging system still is the modified Bell’s staging (42) (Table 1).
Treatment
Guidelines for the management of EOS exist and have 
shown effect on the one hand by reducing the risk of 
EOS but also changing pathogens causing EOS (60,61). 
Similar evidence to support guidance for the management 
of LOS in NICUs is still missing (62). This may be due to 
the more similar spectrum of reported organisms causing 
EOS than in LOS, where we find larger regional variability 
(4,22,40,52,53). Treatment guidelines for EOS focus largely 
on the two most prevalent strains group B streptococcus and 
E. coli. In LOS there are different pathogens and different 
sites of infection (blood, brain, lung, urinary tract, or skin 
and soft tissue) which require different types of antibiotic 
compositions and durations of treatment (21). For the last 
several decades, therefore, treatment for LOS has remained 
largely empirical and focused mainly on antibiotics. 
Antibiotics are hence the most commonly prescribed 
medications in newborn infants requiring intensive care (63). 
Clinical trials to improve treatment are rare because of a 
lack of consensus in definition of sepsis and selection of 
appropriate endpoints (64). As a result, there is inadequate 
evidence from randomized trials in favor of any particular 
antimicrobial regimen (65). 
As even fulminant infections may have minimal and 
unspecific early warning signals, antimicrobial treatment 
must proceed in all suspected cases without delay. 
Understanding the local microbiological epidemiology of 
the patient, the neonatal unit and the hospital as a whole 
is essential in order to choose the appropriate empiric 
therapy (21). As the exact pathogen is not known at onset of 
treatment, initial treatment usually targets many different 
pathogens simultaneously. The resulting intensive use of 
antimicrobials in neonatal units has led to changes in the 
antimicrobial susceptibility patterns of organism (62,66). 
Once the pathogen is identified in culture, usually within 
48 to 72 hours, treatment should therefore be converted 
by switching to the narrowest effective agent or by 
terminating the unspecific course of antibiotics. But the 
knowledge on how to adjust or terminate antibiotic use is 
limited. The most frequent blood culture result, CoNS, 
may mean a contamination. If the culture is negative, then 
this may not automatically mean that the child is free of a 
debilitating pathogen but instead it may be due to previous 
antibiotic exposure, low colony count sepsis, and difficulty 
obtaining an adequate volume of blood for culturing (67). 
Particularly in extremely preterm born infants, previous 
antibiotic exposure is frequent if not ubiquitous due to EOS 
prophylaxis (62). Also, these infants are the ones where 
adequate volume of blood is most difficult to obtain.
Variations in the treatment of LOS, particularly in the 
use of antibiotics, is therefore to be expected. In a study 
enrolling infants receiving >72 hours antibiotic treatment, 
35% received them inappropriately. The overuse was 
largely due to failure to narrow antibiotic coverage after 
microbiologic results were known (66). This result was 
confirmed by a recent study in 2019 on VLBW infants 
in which the most important factor determining duration 
of initial antibiotic treatment was clinical status and not 
laboratory results (68). Along these lines, the California 
Perinatal Quality Care Collaborative recently reported 
a 40-fold variation in antibiotic use rates between units, 
ranging from 2.4% to 97.1% of patient-days. The study 
highlights significant variations in practice and the almost 
certain overuse of antibiotic therapy as the 40-fold variation 
could not be attributable to clinical differences in the 
NICUs, including the rate of positive culture results (69). 
In a survey of guidelines for the use of 41 antimicrobials 
in French NICUs, 444 dosage regimens were identified. 
The number of different dosing regimens varied from 1 
to 32 per drug (70). Another European study including 
89 NICUs found wide variation in dosing of antibiotics, 
with significant under- and overdosing (71).
Obviously, treating infants at even a low risk of a possibly 
lethal infection with antibiotics seems indicated and not 
treating without certainty of no risk is difficult to legitimize. 
But the potentially unnecessary exposure to antibiotics may 
affect the immediate course of the child’s hospitalization 
and its long-term outcome. Studies have linked the number 
of days exposed to antibiotics with subsequent mortality, 
a higher risk for NEC and non-CoNS infections (62). 
Alterations in the gut microbiome, an effect of exposure to 
antimicrobials, may be linked to long-term outcomes such 
as childhood obesity or asthma (62,67). 
Finding ways to limit antibiotic use therefore are 
necessary and have a large potential  both for the 
improvement of care and the limitations of cost. Cost can be 
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reduced by direct reduction of use and, more importantly, 
by the possible reduction of short- and long-term adverse 
outcome. The Choosing Wisely campaign in the US 
charges medical societies with identifying unnecessary tests 
and treatments that contribute to healthcare waste (72). A 
broad selection of stakeholders selected the five foremost 
tests or treatments that cannot be adequately justified on 
the basis of efficacy, safety or cost in newborn medicine. 
As number two, the stakeholders selected ‘avoid routine 
continuation of antibiotic therapy beyond 48 hours for 
initially asymptomatic infants without evidence of bacterial 
infection’ (73). 
Whereas randomized trials for the treatment of LOS 
are missing, the evidence base for antibiotic stewardship 
programs (ASP) aimed at limiting unnecessary antibiotic 
treatment is currently growing. A recent Cochrane review 
summarized 58 randomized controlled trials (RCTs) and 
163 non-randomized studies from adult medicine. They 
concluded that there was high-certainty evidence that 
interventions were effective in increasing compliance 
with antibiotic policy and reducing duration of antibiotic 
treatment. Based on lower quality of evidence, they also 
maintained that lower use of antibiotics probably did not 
increase mortality and likely reduced length of stay (74).
In 2016, the VON partnered with the American Center 
for Disease Control (CDC) to establish an ASP focused 
on decreasing antibiotic overuse in newborns. It was based 
on the CDC recommended 7 core elements: leadership, 
commitment, accountability, drug expertise, action, 
tracking, reporting, and education. In a first assessment, 
Ho et al. analyzed the baseline prevalence and makeup of 
this ASP and assessed the variability of NICU antibiotic use 
rates (75). Among the participating 143 centers completing 
structured self-assessments, no center addressed all 7 core 
elements. There were significant gaps between CDC 
recommendations to improve antibiotic use and antibiotic 
practices during the newborn period and wide variation in 
point-prevalence antibiotic use rates. Seventy-four percent 
of infants who received antibiotics >48 hours did not have 
infections proven by culture documenting ample potential 
for improvement based on the Choosing Wisely initiative 
alone (75). 
Medical treatment for NEC includes bowel decompression 
and rest, fluid resuscitation, antibiotic therapy, and supportive 
care. Antibiotic treatment is indicated as sepsis may result in 
20–30% infants due to translocation of organisms through a 
compromised intestinal barrier (21). Indication for surgical 
intervention is given in cases of pneumoperitoneum or clinical 
deterioration despite maximal medical therapy (76-78).
Prevention
Improving treatment for LOS and NEC is adamant. But an 
even better approach is to avoid either of them altogether. 
As antibiotic overuse carries the risk for adverse short 
and long-term outcome, reducing their use in an ASP can 
be seen as treatment guide and as prevention. Other risk 
factors for LOS and NEC have been amply described and 
may serve as target for prevention. 
LOS has been associated with lack of hygiene as far back 
as 1847 when Ignaz Semmelweis realized that hands play 
an important role in the chain of transmission of bacteria. 
At the obstetrical clinic in Vienna, the German-Hungarian 
physician ordered the use of chlorinated lime solution for 
hand washing and thereby reduced mortality rate due to 
childbed fever from 18% to 2%. According to Dr. Stoll 
et al.’s landmark paper on LOS in 2002, risk factors other 
than above mentioned GA/birth weight or antibiotic 
overuse, are catheters, hyperalimentation, age at first 
feeding, age at full feeding and mechanical ventilation (37). 
These risk factors were later confirmed in other studies 
(79-82), and in 2015 Dr. Stoll herself concluded that “the 
reduction in late-onset sepsis likely reflects increased attention to 
improved hand hygiene, skin care, human milk feeding, uniform 
practices for catheter insertion and care (central line bundles), and 
attention to discontinuing invasive devices when not needed.” (34). 
Risk factors for NEC further include male sex, fetal growth 
restriction and a hemodynamically significant patent ductus 
arteriosus, the latter if treated with indomethacin (83-86). 
However, the key risk factor remains a deficient or abnormal 
microbial colonization of the gut (see above) (6,13,14). This 
deficiency can be met by reducing unnecessary exposure to 
antibiotics, better hygiene, and specific prevention measures 
discussed below.
Prevention strategies largely focus on minimizing the 
listed risk factors. Even though it is meanwhile common 
knowledge that appropriate hand hygiene (HH) reduces 
the risk of LOS, contemporary reports still document 
improvement potential in the compliance rates of hand 
disinfection routines. The most often cited figure for HH 
compliance is 40% and originates back to a review of 34 
studies in 2002 (87). Whereas a current systematic review 
summarizing HH compliance is missing (88), several 
individual reports exist on humble HH compliance. In their 
2018 study, Cunningham et al. describe their response to a 
spike in nosocomial infection in a children’s hospital. After 
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first consulting their records on self-reported compliance 
rates for HH in their hospital, which were high, they 
were astounded that unannounced checks revealed that 
HH compliance was at a low 50%. As previous reports on 
improvement and sustainability of HH compliance did 
not convince them, they applied an approach developed 
in military known as stand-down. As a result, compliance 
increased from less than 65% to more than 95% and was 
sustained for 3.5 years at the time of reporting (89). In a 
neonatal setting, Pessoa-Silva et al. report a sustainable 
increase in HH compliance from 42% to 55% (90), 
whereas Raskind et al. report falling back to their baseline 
89% HH compliance after 3 months (91). Judging from 
the heterogeneity of the reports on compliance and 
sustainability, unannounced observation of local HH seems 
a worth-while approach to test for local improvement 
potential.
Another approach to LOS prevention currently addresses 
central line-associated bloodstream infections (CLABSI), 
one of the major contributors to LOS. CLABSI reduction 
can be achieved by combining evidence-based prevention 
strategies into “bundles”. Bundles mainly focus on avoiding 
central-line insertion whenever possible, minimizing dwell 
times, and careful attention to sterile line maintenance (4,8). 
A recent systematic review and meta-analysis additionally 
lists HH, empowerment of staff, feedback to staff, 
specialized teams, as well as reviewing compliance and check 
lists as reported elements of CLABSI reduction bundles. 
The cumulative analysis of 27 studies from 2002 to 2016 
showed a statistically and clinically significant benefit of 
preventive bundles to avoid CLABSI in neonatal intensive 
care. However, the studies also showed heterogeneity in 
endpoint definitions and implemented measures as well as 
a publication bias towards reporting success rather than 
failure (92). 
An evidence-based overview over which bundle elements 
are most effective is missing and cannot be drawn out 
of the afore mentioned systematic review or individual 
studies (92,93). However, comprehensive guidelines 
exist and recommend specific measures along the lines 
listed above (94,95). Based on these guidelines, a NICU 
in Vienna, Austria, developed an interesting approach 
focusing on simulation training of central line insertion (96). 
Their multidisciplinary team applied a bundle consisting 
of three elements: (I) a simulation-based standardization 
and education of a peripherally inserted central catheter 
insertion technique, (II) improvement of breast milk 
hygiene management by standardized HH trainings for 
mothers and (III) compulsory standardized HH trainings 
for all staff members. As a result, their CLABSI infections 
per 1,000 central line days decreased from 13.9 in 2010 to 
9.5 in 2011 and 4.7 in 2012 (96).
The further preventive measures target both LOS and 
NEC and focus on human milk feeding and onset of feeding, 
or on providing the benefiting components of human milk 
when it is not directly available: donor milk, probiotics, 
prebiotics and lactoferrin. Human milk contains antimicrobial 
proteins and peptides as well as other bioactive molecules. 
They protect the infant against infection, contribute to a 
healthy microbial colonization of the gastrointestinal tract and 
support appropriate maturation of the developing immune 
system (7,8). Microbes present in human milk may act as 
commensal gastrointestinal microorganisms and potentially 
have beneficial effects for the developing gastrointestinal 
tract. The taxa from individual mother’s samples over time 
remains similar, but each mother’s samples differ from other 
mothers’ milk microbiota, suggesting a specific microbial 
ecology for each mother-infant dyad. Individual studies 
have shown that providing the infant with own mother’s 
milk (OMM) decreased rates of LOS, NEC, retinopathy of 
prematurity, lower rates of re-hospitalizations in the first year 
of life, and improved neurodevelopmental outcome (97,98). 
Evidence from a systematic review supporting these findings 
in premature infants is missing (99). However, in their own 
systematic review on neurodevelopmental outcomes of 
preterm infants fed human milk, Lechner and Vohr conclude 
that any intervention that has the potential to decrease 
morbidities with long-term effects (such as LOS and NEC) 
and the potential to increase cognitive ability (by increasing 
white matter development and cortical thickness) must be 
supported even if the reported effect size is small (100).
To avoid deficient or abnormal microbial colonization of 
the gut, implementing evidence-based standardized feeding 
guidelines may help reduce the incidence of NEC (16). 
Although such guidelines are not uniform, they usually 
incorporate an early minimal enteral nutrition phase during 
which 10–20 mL/kg/d of enteral nutrition is provided 
without increase, followed by daily advancement based on 
continued tolerance. Older studies suspected an association 
of NEC with the start of enteral feeding and therefore 
withheld feedings for days to weeks after birth (101).
If human milk is not available, donor milk may be 
an alternative. But even if using donor milk in lieu of 
formula feedings has led to reduced NEC rates in recent 
studies, it is unclear whether donor milk itself protected 
against NEC or whether the avoidance of formula acted 
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as a protective factor (16). Other issues with donor milk 
concern pasteurization, which significantly decreases the 
concentration of many of the protective elements in human 
milk. Also, the effect of the milk may be hampered because the 
GA of the donors’ infants and the infants receiving their milk 
are mismatched or the donor milk may be pooled (7).
Multiple meta-analyses of randomized studies have 
shown that probiotics are associated with reduced rates 
of NEC and LOS (102,103). Yet dissent prevails. Some 
maintain, sufficient evidence is given for probiotics-
prophylaxis (104). Others maintain that evidence is 
missing on which subgroups really require or benefit from 
probiotics (e.g., when used as a supplement to OMM) 
or regarding the unknown long-term effects on immune 
function and metabolism following replacement of a 
maternally derived intestinal microbiome with a dominant 
exogenous bacterial species (105). These reasons and a lack 
of consensus regarding the strain(s), dosage, duration and 
timing of use has prevented many units from adopting it as 
a prevention strategy.
Further preventive approaches concern the commonly used 
technique in NICUs called kangaroo mother care or skin-to-
skin care, where there is close contact between mother and 
infant. This could potentially have a salutary effect on the 
mucosal immune system of the preterm infant (12).
Several RCTs have been undertaken to find alternative 
approaches to treating or preventing LOS and NEC. 
Polyclonal intravenous immunoglobulin (IVIG) targets 
the lack of IgG in preterm infants. In its meta-analysis, a 
2013 Cochrane review found that overall there was a 3% 
reduction in sepsis and a 4% reduction in one or more 
episodes of any serious infection but found not association 
with reductions in other clinically important outcomes, 
including mortality. The authors concluded that it depended 
on costs and the values assigned to the clinical outcomes 
whether IVIG should be implemented and that no further 
studies were warranted (9,106). 
Immune replacement therapies were widely explored 
in the hope of correcting the immune deficiencies and 
thus preventing neonatal infections. Colony-stimulating 
factors (CSF), such as granulocyte CSF and granulocyte 
macrophage CSF, are cytokines that promote the 
proliferation and antimicrobial function of neutrophils, 
monocytes and macrophages. Several clinical trials 
investigated the effect of supplying granulocyte CSF 
(G-CSF) and granulocyte/macrophage (GM-SCF) in the 
prevention and treatment of neonatal sepsis. However, 
a 2003 Cochrane review of ten studies demonstrated no 
significant survival advantage at 14 days from the start 
of therapy (7). This may be because the immune system 
of preterm infants is not simply immature, but rather 
specifically regulated for the early stage of postnatal life (4).
Pentoxifylline is a non-specific phosphodiesterase 
inhibitor with immunomodulatory properties. It may be 
beneficial in preterm neonates with LOS or NEC as its 
effects are more pronounced in neonatal immune cells 
than in adults. A meta-analysis of six RCTs encompassing 
416 infants concluded that Pentoxifylline, when used as 
an adjunct therapy to antibiotics in neonatal sepsis, might 
decrease mortality (relative risk 0.38, 95% CI: 0.20–0.71). 
But the overall quality of evidence was determined as low by 
the authors. They concluded that further large trials were 
needed (107). This may soon be provided by an RCT in 
Australia/New Zealand, which is currently recruiting 1,800 
infants to determine if pentoxifylline can improve long-
term outcome in preterm infants with LOS or NEC (108).
The role of epidermal growth factors, prebiotics, 
glutamine, and oral lactoferrin on reducing the risk of 
NEC has not yet been confirmed. Prebiotics are human 
milk oligosaccharides that promote the growth of beneficial 
commensal probiotics like Bifidobacterium and Bacteroides 
in the healthy breast-fed term infants’ intestine. Lactoferrin 
limits the amount of iron available to pathogenic 
bacteria and promotes growth of commensal bacteria (9). 
Investigations into these products, particularly prebiotics, 
are presently underway (7).
Conclusions
LOS and NEC are multifaceted illnesses that are difficult 
to diagnose, rendering a comparison between health care 
providers difficult. Comparison is further complicated 
because an overall accepted and applicable definition for 
either is missing to date. After decades of research, both 
continue to have a high burden on the health of newborns, 
particularly very preterm born infants.
Empirical therapy for LOS is often inappropriately 
used with unnecessary broad-spectrum antibiotics and a 
prolonged duration of treatment. This leads to an increasing 
number of multidrug-resistant Gram-negative micro-
organisms which poses a serious concern worldwide (51). 
Beyond antibiotics and supportive care, there is presently 
no approved drug for the treatment or prevention of sepsis 
in preterm or term neonates (7).
New findings suggest that many of the long-standing 
practices used to treat or prevent infection or NEC would 
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profit from (I) improved local performance where effective 
care is not provided and (II) local revision of current 
practices in relation to newest findings in basic research 
(e.g., on the function and deficiencies of the preterm 
born immune system and the benefits of OMM). Local 
data collection or better yet, participating in a national 
surveillance system, form the prerequisite for both and have 
led to substantial reduction of LOS (109).
A better implementation of known effective care models 
may then form the basis for novel therapies. Novel therapies 
require proof of effectiveness, usually by performing RCTs. 
As numbers needed to treat are high, neonatal trials are 
commonly performed on a multicenter level. However, if 
the different centers do not observe the same hygiene rules, 
antibiotic stewardship, milk feeding practices, pro-/pre- 
or symbiotic usage, and/or central line removal policies, 
the effect of a new intervention for LOS or NEC may well 
be biased during trials even if randomization is performed 
correctly, because the new treatments most often target the 
same pathways as the prevention practices listed.
This review also reveals several concrete knowledge gaps 
of which the community would greatly profit if they were 
met: evidence to support guidance for the management of 
LOS in NICUs, a systematic review on the effect of OMM 
on LOS or NEC and evidence on the effectiveness of 
probiotics to prevent NEC in infants receiving OMM.
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